Best Allergy Nasal Sprays 2026 Reference Edition

POPULATION · PREGNANCY

Safe Nasal Sprays in Pregnancy: Trimester Guide (2026)

Class-level safety guidance for allergic and pregnancy rhinitis. Every recommendation keyed to MotherToBaby / ACOG / AAAAI.

By BestAllergyNasalSprays Editorial Team — Clinical Pharmacy, Editorial Pool Reviewed by BestAllergyNasalSprays Editorial Team — Pregnancy & Lactation, Editorial Pool
Content updated Evidence reviewed First published

Literature review current through

Why nasal congestion is so common in pregnancy

Pregnancy rhinitis affects roughly one in five pregnant patients (about 20%), is thought to be driven by hormonal changes, and by definition resolves completely within about two weeks after delivery 10 Expert Pre-existing allergic rhinitis often worsens during pregnancy, too. “What’s safe?” is a legitimate, routine question, and the answer depends on drug and trimester.

Safety matrix (pin this)

Trimester × product safety: at a glance

Visual summary of class-level guidance. Always confirm with your OB/GYN.

Trimester × product safety: at a glance Matrix of 3 rows (Trimester 1, Trimester 2, Trimester 3) by 6 columns (Rhinocort, Flonase, Nasonex, Nasacort, Afrin, Saline). RhinocortFlonaseNasonexNasacortAfrinSaline Trimester 1Trimester 2Trimester 3 1st-line Alt Alt Avoid Avoid Safe 1st-line Alt Alt Avoid ≤3 d w/ OB Safe 1st-line Alt Alt Avoid ≤3 d w/ OB Safe
Trimester × product safety: at a glance
RhinocortFlonaseNasonexNasacortAfrinSaline
Trimester 1 1st-line: approvedAlt: approvedAlt: approvedAvoid: contraindicatedAvoid: contraindicatedSafe: approved
Trimester 2 1st-line: approvedAlt: approvedAlt: approvedAvoid: contraindicated≤3 d w/ OB: cautionSafe: approved
Trimester 3 1st-line: approvedAlt: approvedAlt: approvedAvoid: contraindicated≤3 d w/ OB: cautionSafe: approved

First-line: Rhinocort (budesonide)

The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy. 1 Expert A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts. 11 Expert The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis 8 Guideline

Second-line: Flonase, Nasonex, Sensimist

Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician 2 Expert Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018) 4 Expert

Avoid: Nasacort (triamcinolone)

Triamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women. 7 Expert It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset. 3 Expert The FDA Nasacort prescribing information cites animal teratogenicity (cleft palate, cranial malformations) in rats, rabbits, and monkeys at inhaled doses near or below the maximum recommended human nasal dose. Although it is not established that intranasal triamcinolone causes cleft palate in humans, clinicians typically default to Rhinocort (or Flonase / Nasonex as alternatives) in pregnancy because budesonide has the most extensive pregnancy-specific human dataset. Incidental single-exposure before pregnancy awareness is not grounds for panic, but switch to a preferred agent for ongoing use.

Decongestants and oral pseudoephedrine

First-trimester exposure to specific intranasal decongestants, including oxymetazoline, has been linked in hypothesis-generating analyses of the Slone Epidemiology Center Birth Defects Study (Yau 2013) to small increases in the risk of certain rare birth defects; the strongest replicated signals were for oral phenylephrine and oral phenylpropanolamine, with weaker hypothesis-generating signals for intranasal oxymetazoline. 12 Expert Case-control epidemiology has linked first-trimester oral pseudoephedrine to small increased risks of gastroschisis (Werler 2002, OR ~1.8; 95% CI 1.0–3.2) and small-intestinal atresia (OR ~2.0; 95% CI 1.0–4.0), with the signal stronger when pseudoephedrine is combined with acetaminophen. ACOG recommends avoiding pseudoephedrine in the first trimester. 6 Expert

Guidance:

  • Avoid decongestant sprays and oral decongestants in trimester 1.
  • After 20 weeks, ≤3-day oxymetazoline use may be acceptable with OB clearance.
  • Chronic decongestant spray is never recommended (rebound risk applies regardless of pregnancy).

Antihistamine sprays in pregnancy

Human pregnancy data for intranasal azelastine are limited; animal studies have not shown teratogenicity, but published human studies are sparse. Many OB/GYNs prefer intranasal corticosteroids such as budesonide for pregnant patients, where pregnancy-specific data are more robust 5 Expert

Always safe: saline

Because saline nasal sprays and saline irrigation contain no active drug, they are widely recommended as a first-line, drug-free option for nasal symptoms during pregnancy. Consensus guidelines specifically endorse saline irrigation for rhinitis of pregnancy (Rabago 2009) Expert For rinses, use distilled or previously boiled water, never tap water.

NasalCrom (cromolyn sodium)

Cromolyn sodium (NasalCrom) is a mast-cell stabilizer that blocks histamine and other mediator release. Because it is poorly absorbed systemically, it is well tolerated and has an excellent overall safety record Expert Intranasal cromolyn sodium has a long-standing favorable safety record and minimal systemic absorption (Ratner 2002); per LactMed, cromolyn is generally considered acceptable during pregnancy and lactation when symptoms warrant pharmacotherapy, especially as a non-steroid adjunct Expert

Allermi in pregnancy

Allermi is not currently prescribed during pregnancy or breastfeeding Expert Talk to your OB/GYN about medication choice while pregnant; the first-line intranasal steroid is Rhinocort (budesonide). If you want to confirm eligibility for after pregnancy and breastfeeding, check eligibility in 60 seconds.

Summary & recommendations

Summary & Recommendations

  1. Budesonide (Rhinocort) is the pregnancy first-line nasal steroid, most extensive and reassuring data.
  2. Flonase, Nasonex, and Sensimist are reasonable alternatives when Rhinocort is unavailable or ineffective.
  3. Caution with Nasacort in pregnancy: FDA-label animal teratogenicity not established in humans; budesonide is preferred where pregnancy-specific data are stronger.
  4. Avoid oxymetazoline and oral pseudoephedrine in the first trimester.
  5. Saline spray and rinse (distilled water only) are drug-free and always safe.
  6. Always consult your OB/GYN before starting, stopping, or switching any medication in pregnancy.

Publish history

Publish history

  • Quarterly refresh: MotherToBaby fact sheets re-verified; ACOG FAQ link checked.
  • Initial publication.

References

Guidelines

  1. Dykewicz 2020: Rhinitis practice parameter · JACI (2020) https://pubmed.ncbi.nlm.nih.gov/32707227/
  2. ACOG: Medications in pregnancy · ACOG https://www.acog.org/womens-health/faqs/medicines-and-pregnancy

MotherToBaby fact sheets

  1. Budesonide · OTIS https://mothertobaby.org/fact-sheets/budesonide/
  2. Fluticasone · OTIS https://mothertobaby.org/fact-sheets/fluticasone/
  3. Triamcinolone · OTIS https://mothertobaby.org/fact-sheets/triamcinolone/
  4. Mometasone · OTIS https://mothertobaby.org/fact-sheets/mometasone/
  5. Azelastine · OTIS https://mothertobaby.org/fact-sheets/azelastine/
  6. Pseudoephedrine · OTIS https://mothertobaby.org/fact-sheets/pseudoephedrine/

Primary literature

  1. Carmichael 2007: Triamcinolone oral cleft signal · PubMed (2007) https://pubmed.ncbi.nlm.nih.gov/17293188/
  2. Ellegård 2006: Rhinitis in pregnancy · PubMed (2006) https://pubmed.ncbi.nlm.nih.gov/16995855/
  3. Källén 1999: Inhaled budesonide in pregnancy · PubMed (1999) https://pubmed.ncbi.nlm.nih.gov/10498851/
  4. Oxymetazoline pregnancy: NBDPS data · PubMed https://pubmed.ncbi.nlm.nih.gov/23463736/

Related

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.